ADC Therapeutics (ADCT) Other Gross PP&E Adjustments (2019 - 2023)
Historic Other Gross PP&E Adjustments for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$10.3 million.
- ADC Therapeutics' Other Gross PP&E Adjustments fell 5313.06% to -$10.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$10.3 million, marking a year-over-year decrease of 5313.06%. This contributed to the annual value of -$15.8 million for FY2022, which is N/A changed from last year.
- Per ADC Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$10.3 million for Q3 2023, which was down 5313.06% from -$11.0 million recorded in Q2 2023.
- ADC Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at -$3402.0 during Q3 2020, with a 5-year trough of -$15.8 million in Q4 2022.
- Moreover, its 5-year median value for Other Gross PP&E Adjustments was -$7.5 million (2021), whereas its average is -$7.0 million.
- As far as peak fluctuations go, ADC Therapeutics' Other Gross PP&E Adjustments plummeted by 22153433.27% in 2021, and later skyrocketed by 2455.12% in 2022.
- ADC Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at -$4898.0 in 2019, then soared by 30.54% to -$3402.0 in 2020, then plummeted by 221534.33% to -$7.5 million in 2021, then tumbled by 109.38% to -$15.8 million in 2022, then surged by 34.93% to -$10.3 million in 2023.
- Its Other Gross PP&E Adjustments was -$10.3 million in Q3 2023, compared to -$11.0 million in Q2 2023 and -$11.2 million in Q1 2023.